BioSpace News Archive

New Jersey Innovation Institute (NJII), a New Jersey Institute of Technology (NJIT) Corporation, has signed an Industry Participation Agreement with Pall Corporation (Pall) to support the development of its BioPharmaceutical Innovation iLab.

Dr. Saltarelli was most recently Executive Vice President and Chief Medical Officer at Syntimmune and joins Entrada following more than 30 years in the biomedical and biopharmaceutical sectors.

One Drop, a leader in the development of digital therapeutics solutions for people with diabetes and related conditions, today announced a partnership with Amazon’s exclusive health brand, Choice.

Koneksa Health, a private company that enables the biopharmaceutical industry to develop new medicines using digital biomarkers and novel clinical endpoints, announced today that its poster was presented during the 2019 American Society for Clinical Pharmacology and Therapeutics meeting, “From Molecule to Patient,” March 13-16, 2019, in Washington, D.C.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced the addition of Dr. Stefanie Johns to the Company’s Scientific Advisory Board.

Stanford Medicare Advantage plan seeks sustainable growth and continued innovations to serve seniors in collaboration with Lumeris

ValoremRx Specialty Solutions, the group purchasing organization (GPO) formed by a joint venture between Express Scripts and Walgreens, today announced its new collaboration with Kroger Specialty Pharmacy

Henry Schein Financial Services (HSFS), a subsidiary of Henry Schein, Inc. (Nasdaq: HSIC), today celebrates its 20th anniversary delivering customized financial and business solutions that help oral health and medical practitioners improve operational efficiency.

Proven digital health innovator and investor to help advance the Company’s mission to reshape the pharmaceutical manufacturing landscape

Indee Labs announced the publication of a proof-of-concept study demonstrating the efficacy of its gene-modified cell therapy (GMCT) development and manufacturing technology in Nature’s Scientific Reports